To validate this association, we established bladder cancer cell lines with exogenous expression of TACC3 or E2F1 (Fig. 5c), and as shown in Fig. 5d, the overexpression of TACC3 or E2F1 caused cellular hypersensitivity to cisplatin. The gene discussed is TACC3; the disease is urinary bladder cancer.